The common stock is listed on the Nasdaq Global Market

Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 17,391,832 shares of common stock of Biodesix, Inc. Davis Polk also advised the placement agents in connection with a concurrent private placement of 760,857 shares of Biodesix’s Series A convertible non-voting preferred stock convertible into 40 shares of common stock for each share. The conversion of the Series A convertible non-voting preferred stock is subject to receiving stockholder approval at Biodesix’s 2024 annual meeting of stockholders. Biodesix will receive an aggregate of $55 million of gross proceeds from the offerings. Biodesix’s common stock is listed on the Nasdaq Global Market under the symbol “BDSX.”

Biodesix, headquartered in Louisville, Colorado, is a leading diagnostic solutions company with a focus in lung disease. In addition to diagnostic tests, Biodesix provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associate Steven Glendon. Counsel Alon Gurfinkel and associates Justin Corvino and Isaiah B. Kramer provided tax advice. The intellectual property team included partner David R. Bauer and associates Brette L. Trost and Austin Fuss. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post